What is the recommended dosing schedule for low‑dose naltrexone in weight management, including titration, duration, contraindications, and monitoring?

Naltrexone Dosing for Weight Management

Standard Dosing Protocol for Naltrexone-Bupropion (Contrave®)

For weight management, naltrexone is FDA-approved only in combination with bupropion as Contrave®, not as low-dose naltrexone monotherapy. 1, 2

Titration Schedule

• Week 1: 1 tablet (8 mg naltrexone/90 mg bupropion) once daily in the morning 2, 3, 4

• Week 2: 1 tablet twice daily (morning and evening) 2, 3, 4

• Week 3: 2 tablets in the morning, 1 tablet in the afternoon 2, 3, 4

• Week 4 and beyond: 2 tablets twice daily (maintenance dose = 32 mg naltrexone/360 mg bupropion daily) 2, 3, 4

• The second dose should be taken before early afternoon (not late in the day) to minimize insomnia risk 2, 3

• Slower titration or submaximal doses may be used if adverse effects occur while maintaining therapeutic benefit 5

Treatment Duration and Efficacy Assessment

• At 12 weeks on maintenance dose: Assess whether the patient has achieved ≥5% loss of baseline body weight 2, 3, 4
• If <5% weight loss at 12 weeks: Discontinue naltrexone-bupropion, as the patient is likely a poor responder 2, 3, 4
• Expected weight loss: Mean 11.7% body weight reduction at 56 weeks in responders 6; real-world data show 8.8–10.0% weight loss at 12 months 7, 5
• Continue treatment beyond 12 weeks only if adequate response is demonstrated 1, 2

Absolute Contraindications

• Chronic opioid therapy: Naltrexone precipitates severe opioid withdrawal 2, 3, 4, 8
• Uncontrolled hypertension: Both components can elevate blood pressure 2, 3, 4
• Seizure disorders or conditions predisposing to seizures (eating disorders, brain tumor, stroke, head trauma) 2, 3, 4
• Abrupt discontinuation of alcohol, benzodiazepines, or antiepileptic drugs (increases seizure risk) 2, 4
• Current or recent MAOI use (within 14 days) 2, 4
• Pregnancy or inadequate contraception: All weight management formulations containing bupropion are contraindicated 2
• Moderate to severe hepatic impairment: Maximum dose 1 tablet daily 2, 3, 4
• End-stage renal disease: Avoid entirely 2, 4

Dose Adjustments for Special Populations

• Moderate to severe renal impairment (eGFR <90 mL/min): Reduce total daily dose by 50% (1 tablet twice daily maximum) 2, 3, 4
• Moderate to severe hepatic impairment: Do not exceed 1 tablet daily (8 mg naltrexone/90 mg bupropion) 2, 3, 4
• Older adults: Consider starting at lower doses and titrating more slowly 2

Critical Monitoring Requirements

Cardiovascular Monitoring

• Baseline: Measure blood pressure and heart rate before initiation 2, 3, 4
• During titration and first 12 weeks: Weekly to biweekly blood pressure and heart rate checks 2, 3, 4
• Ongoing: Periodic cardiovascular monitoring throughout treatment 2, 3
• Modest but statistically significant increases in systolic and diastolic blood pressure occur with naltrexone-bupropion 3

Neuropsychiatric Monitoring

• Weeks 1–2: Assess for suicidal ideation, agitation, irritability, anxiety, depression, and unusual behavioral changes 2, 3, 4
• Black box warning: Increased risk of suicidal thoughts in patients <24 years, especially during first 1–2 months 2, 4
• Monitor at each visit for mood changes and neuropsychiatric adverse effects 2, 3

Hepatic Monitoring

• Baseline and periodic liver function tests recommended, as naltrexone can cause hepatocellular injury at higher doses 2

Seizure Risk Monitoring

• Seizure risk is approximately 0.1% (1 in 1,000) at the standard 360 mg/day bupropion dose 2, 4
• Do not exceed 360 mg bupropion daily (four Contrave® tablets) to maintain seizure risk at 0.1% 2, 4

Common Adverse Effects

• During buildup phase: Nausea/vomiting (23.5%), headaches (19.4%), constipation (28.6%) 7
• At optimal dosage: 39.8% experience side effects, with 33% reporting multiple symptoms 7
• Gastrointestinal effects (nausea, constipation) are common and may be intensified when combined with other medications 3, 4
• Anxiety rates: 0.6–5.4% (not significantly different from placebo at 0.2–4.3%) 3

Discontinuation and Adherence

• High discontinuation rates: 52.7% discontinue within 12 months in real-world settings 7
• Reasons for discontinuation: Adverse effects, lack of efficacy, cost, or patient preference 7, 5
• Before procedures requiring opioid analgesia: Discontinue naltrexone-bupropion (e.g., before colonoscopy with fentanyl) 3, 4
• Naltrexone-bupropion should be part of a comprehensive plan including reduced-calorie diet, increased physical activity, and behavioral support 1, 8, 6

Low-Dose Naltrexone (LDN) Monotherapy

Low-dose naltrexone (1–5 mg daily) is NOT FDA-approved for weight management and lacks robust evidence for this indication. 9, 10

• LDN has been studied primarily for chronic pain, fibromyalgia, Crohn's disease, and multiple sclerosis—not obesity 9, 10
• Naltrexone monotherapy does not induce weight loss in obese individuals 11
• Effective doses for chronic pain range from 0.1–4.5 mg daily, typically 4.5 mg, but are idiosyncratic and require individual titration 12, 10
• For weight management, use only the FDA-approved naltrexone-bupropion combination, not LDN monotherapy 1, 2, 6

Clinical Advantages and Patient Selection

• Ideal candidates: Patients with strong food cravings or addictive eating behaviors, as naltrexone blocks opioid-mediated reward pathways 4, 6
• Comorbid conditions: May benefit patients with depression or desire for smoking cessation (bupropion component) 1
• Post-bariatric surgery: Equally effective in patients experiencing weight regain after metabolic and bariatric surgery (median 10.0% weight loss at 12 months) 5
• Mechanism: Targets POMC neurons to prevent endogenous negative feedback, decreasing appetite and improving weight-related outcomes 6

Critical Pitfalls to Avoid

• Do not use naltrexone-bupropion in patients on chronic opioid therapy—it will precipitate withdrawal 2, 3, 4, 8
• Do not exceed 360 mg bupropion daily (four tablets)—seizure risk increases markedly above this threshold 2, 4
• Do not skip cardiovascular monitoring during the first 12 weeks—this period carries the highest risk for blood pressure elevations 2, 3, 4
• Do not continue beyond 12 weeks if <5% weight loss is achieved—discontinue in poor responders 2, 3, 4
• Do not omit intensive neuropsychiatric monitoring in weeks 1–2—highest risk for emergent suicidal ideation 2, 4
• Do not use in patients with eating disorders (bulimia or anorexia nervosa)—bupropion markedly raises seizure risk in this population 2, 4